Search for: [Abstract = "e results of the study suggest the potential utility of ex vivo synthesized cytokines as a biomarker of SAP. The aim of the second study was to determine the clinical utility of lipopolysaccharide binding protein \(LBP\) and soluble CD14 \(sCD14\) as risk markers of SAP. Three hundred thirty\-one patients with ischemic stroke were included into study \(median age\: 71 years\; 47.4% female\). Blood samples were taken within 24 hours after stroke onset. SAP was diagnosed in 13% of patients. Patients with SAP had higher plasma levels of LBP \(median\: 19.4 vs 15.3 μg∕mL, P < 0.01\) and sCD14 \(median\: 1.5 vs 1.4 μg∕mL, P = 0.04\) compared to patients without SAP. In univariate logistic regression analysis, higher LBP and sCD14 levels were associated with an increased risk of SAP \(OR\: 1.09, 95%CI\: 1.05 \- 1.13, P<0.01 and OR\: 2.76, 95%CI\: 1.31 \- 5.82, P<0.01, respectively\). In multivariate analysis adjusted for age, National Institute of Health Stroke Scale \(NIHSS\) score, and atrial fibrillation, a higher level of LBP \(OR\: 1.09, 95%CI\: 1.05\-1.13, P<0.01\), but not sCD14 \(OR\: 2.16, 0.94\-4.97, P=0.07\), was associated with SAP. The AUC for the clinical model of SAP that included age, NIHSS and atrial fibrillation was 0.80. Discriminatory ability of both LBP and sCD14 were inferior to the clinical model \(AUC\: 0.67 and 0.60, respectively\). Moreover, addition of LBP \(AUC\: 0.84, P=0.11\) or sCD14 \(AUC\:"]

Number of results: 1